Keytruda – Page 5 – pharmaceutical daily

October 2, 2015 Off

FDA: Accelerated approval for Keytruda for patients with advanced (NSCLC) lung cancer

accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC)

October 2, 2015 Off

Merck and DNAtrix to evaluate the efficacy and safety of DNX-2401

By Dino Mustafić

Merck, known as MSD outside the United States and Canada, and DNAtrix announced on Thursday that they have entered into an oncology clinical study collaboration to evaluate the efficacy and safety of DNX-2401, DNAtrix’s oncolytic immunotherapy, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 2, multi-centered study of patients with recurrent glioblastoma, the most aggressive form of brain cancer for which there is no cure.